使用多准则决策分析方法为印度新冠疫苗开发选择框架
研究遵循ISPOR指南,采用多准则决策分析(MCDA)框架,在十项准则下比较七种疫苗,通过三轮虚拟研讨会获取公民、私立医院和公共卫生机构的意见与权重,为印度背景下的决策者提供疫苗选择参考。成本、效力和操作评分权重最高,Janssen在六个场景组中四个得分最高,概率敏感性分析中Covaxin、Janssen和Sputnik为前三位。
要点
- 成本、效力和操作评分在利益相关者中权重最高。
- 六个场景组中Janssen在四组得分最高,得益于单剂接种优势。
- 概率敏感性分析中Covaxin、Janssen和Sputnik为前三位选择。
核心结论
- 基于研究时可得数据和利益相关者偏好,Covaxin、Janssen和Sputnik是优先选项。
- 带动态性能矩阵的选择框架是有价值的工具,可适应不同人群并随疫苗选项和证据增加而扩展。
研究设计与样本
- 遵循ISPOR指南的MCDA过程,比较七种疫苗选项,使用十项准则。
- 通过三轮虚拟研讨会获取公民、私立部门医院和公共卫生组织的意见与权重。
- 将可得证据重新缩放并纳入性能矩阵,计算不同组的最终得分,并进行多种敏感性分析评估排名一致性。
主要发现
- 成本、效力和操作评分在利益相关者中权重最高。
- 六个场景组中Janssen在四组得分最高,由单剂接种优势驱动。
- 总体组概率敏感性分析中Covaxin、Janssen和Sputnik为前三位选项。
- 参与者表示可得性、WHO批准和安全性等在考虑疫苗时至关重要。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccines were crucial in controlling the Covid-19 pandemic. As more vaccines receive regulatory approval, stakeholders will be faced with several options and must make an appropriate choice for themselves. We proposed a multi-criteria decision analysis (MCDA) framework to guide decision-makers in comparing vaccines for the Indian context. METHODS: We adhered to the ISPOR guidance for the MCDA process. Seven vaccine options were compared under ten criteria. Through three virtual workshops, we obtained opinions and weights from citizens, private-sector hospitals, and public health organisations. Available evidence was rescaled and incorporated into the performance matrix. The final score for each vaccine was calculated for the different groups. We performed different sensitivity analyses to assess the consistency of the rank list. RESULTS: The cost, efficacy and operational score of the vaccines had the highest weights among the stakeholders. From the six scenario groups, Janssen had the highest score in four. This was driven by the advantage of having a single dose of vaccination. In the probabilistic sensitivity analysis for the overall group, Covaxin, Janssen, and Sputnik were the first three options. The participants expressed that availability, WHO approvals and safety, among others, would be crucial when considering vaccines. CONCLUSIONS: The MCDA process has not been capitalised on in healthcare decision-making in India and LMICs. Considering the available data and stakeholder preference at the time of the study, Covaxin, Janssen, and Sputnik were preferred options. The choice framework with the dynamic performance matrix is a valuable tool that could be adapted to different population groups and extended based on increasing vaccine options and emerging evidence. *ISPOR - The Professional Society for Health Economics and Outcomes Research.
引用
- George TK, Nair NP, Singh AK, et al. Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach. Vaccine. 2023. PMID: 37183072. doi:10.1016/j.vaccine.2023.04.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。